Abstract
Background: The COVID-19 pandemic disrupted the normal delivery of HIV care, altered social support networks, and caused economic insecurity. People with HIV (PWH) are vulnerable to such disruptions, particularly if they have a history of substance use. We describe engagement in care and adherence to antiretroviral therapy (ART) for PWH during the pandemic. Methods: From May 2020 to February 2021, 773 PWH enrolled in 6 existing cohorts completed 1495 surveys about substance use and engagement in HIV care during the COVID-19 pandemic. We described the prevalence and correlates of having missed a visit with an HIV provider in the past month and having missed a dose of ART in the past week. Results: Thirteen percent of people missed an HIV visit in the past month. Missing a visit was associated with unstable housing, food insecurity, anxiety, low resiliency, disruptions to mental health care, and substance use including cigarette smoking, hazardous alcohol use, cocaine, and cannabis use. Nineteen percent of people reported missing at least one dose of ART in the week prior to their survey. Missing a dose of ART was associated with being a man, low resiliency, disruptions to mental health care, cigarette smoking, hazardous alcohol use, cocaine, and cannabis use, and experiencing disruptions to substance use treatment. Conclusions: Social determinants of health, substance use, and disruptions to mental health and substance use treatment were associated with poorer engagement in HIV care. Close attention to continuity of care during times of social disruption is especially critical for PWH.
Original language | English (US) |
---|---|
Article number | 109355 |
Journal | Drug and Alcohol Dependence |
Volume | 241 |
DOIs | |
State | Published - Dec 1 2022 |
Funding
This work was supported by grants from the National Institutes of Health ( U24 DA044554 ; K01 AA028193 ; K01 AI125087 ; K24 AA027483 ; K08 MH113094 ; U01 DA036935 ; U01 AI069918 ; T32 HP10025 ; U01 DA0251525 ; U01 DA036297 ; U01 DA036267 ; K24 AI118591 ). This work was supported by grants from the National Institutes of Health (U24 DA044554; K01 AA028193; K24 AA027483; K08 MH113094; U01 DA036935; U01 AI069918; T32 HP10025; U01 DA036297; U01 DA036267). The funding source had no role in the design and conduct of the study, the analysis and interpretation of data, or in the preparation, review, or approval of the manuscript.
Keywords
- Antidepressant therapy
- Care cascade
- Depression
- Depressive symptoms
- Viral non-suppression
ASJC Scopus subject areas
- Toxicology
- Pharmacology
- Psychiatry and Mental health
- Pharmacology (medical)